Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Transcatheter Bioprosthetic Aortic Valve Dysfunction: What We Know So Far

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Women With Diabetes Are at Increased Relative Risk of Heart Failure Compared to Men: Insights From UK Biobank

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Influence of Timing and Predicted Risk on Mortality in Impella-Treated Infarct-Related Cardiogenic Shock Patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. BLTR1 and CD36 Expressing Microvesicles in Atherosclerotic Patients and Healthy Individuals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. First-in-human results of the OMEGA™ Left Atrial Appendage Occluder for Patients with Non-Valvular Atrial Fibrillation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Impact of early hospital discharge on clinical outcomes after transcatheter aortic valve implantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Contemporary management of severe symptomatic bicuspid aortic valve stenosis: the BiTri Registry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Transcatheter aortic valve replacement (TAVR) is an established alternative to surgical valve replacement for patients with severe aortic stenosis (AS) and increased surgical risk. On the basis of the favorable outcomes of recent randomized clinical trials conducted in intermediate and low risk populations, TAVR is expected in the near future to be offered to patients not only at lower surgical risk, but also with longer life expectancy. In this particular subset, the long-term durability of the bioprosthetic valve is of critical importance. The European Association of Percutaneous Cardiovascular Interventions (EAPCI), the European Society of Cardiology (ESC), and the European Association for Cardio-Thoracic Surgery (EACTS) recently introduced standardized criteria to define structural valve deterioration (SVD) and valve failure of transcatheter and surgical aortic bioprosthesis-this with the aim to generate uniformity in data reporting in future studies assessing long-term durability of aortic bioprosthesis. On this background, the aim of this article is to review the definition, incidence and predictors of transcatheter bioprosthetic valve dysfunction, including structural and non-structural valve deterioration (SVD/NSVD), valve thrombosis, and endocarditis.

OriginalsprogEngelsk
TidsskriftFrontiers in Cardiovascular Medicine
Vol/bind6
Sider (fra-til)145
ISSN2297-055X
DOI
StatusUdgivet - 2019

Bibliografisk note

Copyright © 2019 Sawaya, Jørgensen, Søndergaard and De Backer.

ID: 59143716